Moderna (NASDAQ:MRNA) Stock Price Down 4.7% – Here’s What Happened

Moderna, Inc. (NASDAQ:MRNA) shares traded down 4.7% during trading on Monday . The stock traded as low as $37.08 and last traded at $37.56. 2,802,809 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 12,083,261 shares. The stock had previously closed at $39.42.

Analyst Ratings Changes

A number of brokerages have issued reports on MRNA. The Goldman Sachs Group downgraded Moderna from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $99.00 to $51.00 in a research report on Wednesday, January 29th. Sanford C. Bernstein initiated coverage on Moderna in a research report on Thursday, October 17th. They issued a “market perform” rating and a $55.00 price target for the company. Jefferies Financial Group cut their price objective on shares of Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a research report on Tuesday, October 15th. Hsbc Global Res raised shares of Moderna from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. Finally, Berenberg Bank upped their price target on shares of Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a report on Thursday, January 16th. Four analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Moderna currently has an average rating of “Hold” and a consensus price target of $67.26.

Moderna Trading Down 6.3 %

The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. The company has a market capitalization of $14.22 billion, a P/E ratio of -6.35 and a beta of 1.60. The company’s fifty day simple moving average is $40.89 and its 200-day simple moving average is $60.43.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. The firm had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period last year, the firm earned ($1.39) earnings per share. Research analysts predict that Moderna, Inc. will post -9.18 earnings per share for the current year.

Insider Transactions at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the sale, the insider now owns 19,717 shares of the company’s stock, valued at $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In the last three months, insiders sold 2,664 shares of company stock valued at $115,210. Corporate insiders own 15.70% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Blue Trust Inc. grew its stake in shares of Moderna by 365.6% during the third quarter. Blue Trust Inc. now owns 731 shares of the company’s stock worth $49,000 after acquiring an additional 574 shares during the last quarter. Wilmington Savings Fund Society FSB increased its stake in Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after purchasing an additional 587 shares in the last quarter. Venturi Wealth Management LLC raised its holdings in shares of Moderna by 286.2% in the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after buying an additional 664 shares during the last quarter. Compass Planning Associates Inc purchased a new stake in shares of Moderna during the fourth quarter valued at $37,000. Finally, Larson Financial Group LLC increased its position in shares of Moderna by 53.5% in the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after acquiring an additional 317 shares during the period. 75.33% of the stock is owned by institutional investors and hedge funds.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.